You are here: Industry Insights > Kidney Cancer

News List

Roche pulls EU application for Tecentriq in kidney cancer biopharmadive
November 22, 2018
Roche has withdrawn an application to the European Medicines Agency that sought an expanded approval for its immunotherapy Tecentriq in advanced kidney cancer, concluding in a letter to the regulator data were insufficient to support a label extension.
Half of all kidney cancer patients initially misdiagnosed pharmatimes
November 01, 2018
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.
Half of all kidney cancer patients initially misdiagnosed pharmafile
November 01, 2018
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.
Merck, Pfizer intend to file Bavencio, Inlyta combo pharmatimes
September 13, 2018
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Blood test could detect kidney cancer up to five years earlier pharmatimes
August 16, 2018
Scientists have discovered a marker in the blood that could predict the risk of developing kidney cancer.
Pfizer pulls plug on Inlyta trial pharmatimes
July 17, 2018
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
BMS’ Opdivo/Yervoy combo cleared for kidney cancer pharmatimes
July 16, 2018
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
EU OKs first-line use of Ipsen’s Cabometyx pharmatimes
July 12, 2018
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Evolutionary path of kidney cancer tracked, “born to be bad” type discovered pharmafile
April 16, 2018
A massive effort funded by Cancer Research UK has been able to track the different evolutionary pathways of kidney cancer that could change how certain types are treated.
FDA expands use of Pfizer's Sutent in kidney cancer pharmafile
November 20, 2017
Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma– the most common kind of kidney cancer – following nephrectom

Previous page 1 2 3 4 Next page